Images List Premium Download Classic

Allergic Rhinitis

Allergic Rhinitis-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Trk-inhibiting compound
Ono Pharmaceutical Co., Ltd.
November 30, 2017 - N°20170340634

The present invention provides a drug containing a compound having trk-inhibiting activity as an active ingredient in prophylaxis and/or therapy for trk-related diseases such as pain, pruritus, lower urinary tract dysfunction, asthma, allergic rhinitis, inflammatory bowel disease or chagas disease. A compound represented by the general formula (i), wherein all symbols represent the same meanings as described in the ...
Treatment of allergic rhinitis using a combination of mometasone and olopatadine
Glenmark Pharmaceuticals S.a.
November 23, 2017 - N°20170333449

The present invention relates to a method of treating allergic rhinitis in a subject (e. G., a human) in need thereof comprising nasally administering to the subject an effective amount of a fixed-dose pharmaceutical composition comprising mometasone or its salt and olopatadine or its salt.
Pyrazolopyrimidine compounds
Glenmark Pharmaceuticals S.a.
October 12, 2017 - N°20170290910

Wherein r1 is n-c1-6alkyl or c1-2alkoxyc1-2alkyl-, r2 is halo, oh or c1-3alkyl, m is an integer having a value of 4, 5, 6 or 7, n is an integer having a value of 0, 1, 2 or 3, and p is an integer having a value of 0, 1 or 2, are inducers of human interferon. Compounds which induce human interferon may be ...
Allergic Rhinitis Patent Pack
Download + patent application PDFs
Allergic Rhinitis Patent Applications
Download + Allergic Rhinitis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Allergic Rhinitis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Composition for the prevention and/or treatment of allergy symptoms
Ntc S.r.l.
September 14, 2017 - N°20170258864

The present invention relates to a pharmaceutical composition or a food supplement composition and use thereof in the prevention and/or treatment of allergy symptoms, preferably allergic rhinitis and/or allergic conjunctivitis symptoms. In particular, the composition according to the invention comprises at least one slow release component comprising quercetin and at least one fast release component comprising an extract ...
Nasal stimulation for rhinitis, nasal congestion, and ocular allergies
Oculeve, Inc.
August 24, 2017 - N°20170239459

Described here are devices, systems, and methods for treating one or more conditions, such as allergic rhinitis, non-allergic rhinitis, nasal congestion, ocular allergy, and/or symptoms associated with these conditions, by providing stimulation to nasal or sinus tissue. In some variations, the handheld devices may have a stimulator body and a stimulator probe having one or more nasal insertion prongs, ...
Phenyloxadiazole derivatives as pgds inhibitors
Oculeve, Inc.
August 17, 2017 - N°20170231990

Wherein r1, r2 and r3 are as defined herein, a pharmaceutical composition comprising the compound, intermediates and processes for making said compounds, and the use of the compound to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma, chronic obstructive pulmonary disease (copd) and age-related macular degeneration (amd).
Allergic Rhinitis Patent Pack
Download + patent application PDFs
Allergic Rhinitis Patent Applications
Download + Allergic Rhinitis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Allergic Rhinitis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Liquid formulation comprising montelukast or pharmaceutically acceptable salt thereof and method for preparing same
Hanmi Pharm. Co., Ltd.
June 08, 2017 - N°20170157108

The present invention relates to a liquid formulation comprising a solubilizer and montelukast or pharmaceutically acceptable salt thereof in a solution state as an active ingredient, and a method for preparing same. The liquid formulation of the present invention allows montelukast or pharmaceutically acceptable salt thereof to be substantially dissolved and present in a solution state, thereby preventing decrease of ...
2-(2-aminocyclohexyl)amino-pyrimidine-5-carboxamides as spleen tyrosine kinase(syk) inhibitors
Hanmi Pharm. Co., Ltd.
May 25, 2017 - N°20170145019

The present invention relates to compounds of formula (ia), (ib) or (ic): to pharmaceutically acceptable salts therefore and to pharmaceutically acceptable solvates of said compounds and salts, wherein the substituents are defined herein; to compositions containing such compounds; and to the uses of such compounds in the treatment of various diseases, particularly asthma, copd, allergic rhinitis, chronic sinusitis, atopic dermatitis, ...
Humanized anti-ige antibodies that crosslink cd23 on b lymphocytes but do not sensitize mast cells
Academia Sinica
May 04, 2017 - N°20170121425

A novel humanized anti-ige antibody is disclosed. The antibody is capable of binding to free ige, membrane-bound ige on b lymphocytes, ige bound by cd23, but not to ige bound by high-affinity ige. Fc receptor on mast cells. The present invention relates to the treatment of ige-mediated diseases, including allergic asthma, allergic rhinitis, atopic dermatitis, food allergy, chronic spontaneous (idiopathic) ...
Novel compounds
Academia Sinica
March 23, 2017 - N°20170080085

Wherein r1 is n-c4-6alkyl or c1-2alkoxyc1-2alkyl-; r2 is hydrogen or methyl; each r3 is hydroxy, halo or n-c1-3alkyl; m is an integer having a value of 2 to 4; n is an integer having a value of 0 to 3; and p is an integer having a value of 0 to 2, are inducers of human interferon. Compounds ...
New pyrazolyl-substituted heteroaryls and their use as medicaments
Academia Sinica
March 16, 2017 - N°20170073333

And the use of these aforementioned compounds for the treatment of diseases such as asthma, copd, allergic rhinitis, allergic dermatitis, lupus erythematodes, lupus nephritis and rheumatoid arthritis.
Pyrrolo[3,2-d]pyrimidine derivatives as inducers of human interferon
Academia Sinica
March 02, 2017 - N°20170057963

Wherein r1 is hydrogen, methyl or —(ch2)2or3, r2 is methyl or —(ch2)2or4, or r1 and r2, together with the nitrogen atom to which they are attached, are linked to form a 5- or 6-membered heterocyclyl wherein the 6-membered heterocyclyl is optionally substituted by two hydroxy substituents; r3 and r4 are each independently hydrogen or methyl; and ...
Trk-inhibiting compound
Ono Pharmaceutical Co., Ltd.
February 02, 2017 - N°20170027939

The present invention provides a drug containing a compound having trk-inhibiting activity as an active ingredient in prophylaxis and/or therapy for trk-related diseases such as pain, pruritus, lower urinary tract dysfunction, asthma, allergic rhinitis, inflammatory bowel disease or chagas disease. A compound represented by the general formula (i), wherein all symbols represent the same meanings as described in the ...
Allergic Rhinitis Patent Pack
Download + patent application PDFs
Allergic Rhinitis Patent Applications
Download + Allergic Rhinitis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Allergic Rhinitis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Heteroaryl syk inhibitors
Boehringer Ingelheim International Gmbh
January 12, 2017 - N°20170008896

The invention relates to new substituted heteroaryls of formula 1 wherein a is selected from the group consisting of n and ch d is selected from the group consisting of ch, n, nh, e is c, t is selected from the group consisting of c and n, g is selected from the group consisting of c and n, and wherein each ...
Therapeutic agent for rhinitis
Boehringer Ingelheim International Gmbh
January 12, 2017 - N°20170007673

Means for solving the problem is a therapeutic preparation for rhinitis, in particular allergic rhinitis, comprising c-type natriuretic peptide (cnp) or b-type natriuretic peptide (bnp) as the active ingredient.
Ionic aqueous compositions
Gerolymatos International S.a.
January 05, 2017 - N°20170000817

Disclosed herein are ionic aqueous compositions useful as nasal passage washes to aid in the resorption of edema of the respiratory mucosa, e. G., the nasal mucosa, for the treatment of respiratory tract and/or respiratory mucosal-related conditions, including, e. G., chronic rhinosinusitis, sinusitis, allergic rhinitis and nasal polyps. The composition includes an ionic aqueous solution and algae-derived constituents, such ...
Use of egg yolk oil and the benzopyrene-eliminated egg yolk oil in the treatment of ...
Harbin Medical University
December 22, 2016 - N°20160367604

The application of egg yolk oil, as well as benzopyrene-eliminated egg yolk oil, is prepared for medicaments for the treatment of allergic rhinitis. By topical application of egg yolk oil in the nasal cavity, symptoms of allergic rhinitis could be improved significantly. After topical treatment with egg yolk oil, levels of inflammatory cytokines il-4 and ige antibodies in lymphocytes of ...
Materials for treating and preventing mucosa related disease
Aihol Corporation
December 15, 2016 - N°20160361347

Provided is a hyaluronic acid (ha) composition for use in treating or preventing mucosa related disorders or diseases including a mixture of has having different average molecular weights and different rheological, isolation, tissue scaffold and degradation properties. The resulting formulation demonstrates an optimal balance between adhesion, tissue scaffold and treating time on the treatment and prevention of mucosa related disorders ...
Furo[3, 2-b] pyrr0l-3-ones as cathespin s inhibitors
Aihol Corporation
December 15, 2016 - N°20160361295

Compounds of formula (i) exhibit surprisingly high efficacies for human cathepsin s, excellent selectivity verses other mammalian cathepsins and are useful for treatment of diseases such as rheumatoid arthritis, multiple sclerosis, myasthenia gravis, transplant rejection, diabetes, sjogrens syndrome, grave's disease, systemic lupus erythematosis, osteoarthritis, psoriasis, idiopathic thrombocytopenic purpura, allergic rhinitis, asthma, atherosclerosis, obesity, chronic obstructive pulmonary disease and chronic pain.
Pharmaceutical composition including dead cells of lactobacillus acidophilus lb to treat or prevent allergic disease
Aihol Corporation
November 10, 2016 - N°20160324906

Disclosed is a pharmaceutical composition including dead cells of lactobacillus acidophilus lb strain as an active ingredient for treating or preventing an allergic disease, and may be used to treat and prevent ige-mediated allergic diseases and non-ige-mediated allergic diseases such as atopic dermatitis, allergic rhinitis, allergic conjunctivitis, urticaria, and pollinosis by reducing the total content of ige in the blood.
Human antibody molecules for il-13
Medimmune Limited
September 29, 2016 - N°20160280779

Specific binding members, in particular human anti-il-13 antibody molecules and especially those which neutralize il-13 activity. Methods for using anti-il-13 antibody molecules in diagnosis or treatment of il-13 related disorders, including asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and hodgkin's lymphoma.
Loading